PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED WITH ERIBULIN IN COMBINATION WITH MEN1611 -THE SABINA STUDY-

Phase 2

Recruiting

Conditions: Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic or non-metaplastic triple negative breast cancer.
Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic HR-positive/HER2-negative breast cancer

Registration Number: 2024-512963-30-00

Lead Sponsor: Medica Scientia Innovation Research S.L.

Brief Summary: To assess the efficacy of MEN1611 in combination with eribulin as

determined by the clinical benefit rate (CBR) in:

1.Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic or non metaplastic triple negative breast

cancer.

2. Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic HR-positive/HER2-negative breast

cancer.

Detailed Description: This is a multicenter, two-cohort, non-comparative, open-label, phase II clinical trial to assess:

* the efficacy of MEN1611 in combination with eribulin as determined by the clinical benefit rate (CBR) in unresectable locally advanced or metastatic HR-known/HER2-negative, PIK3CA/ PTEN-altered MpBC patients (Cohort A), and

* the efficacy of MEN1611 as monotherapy as determined by the objective response rate (ORR) at 6 weeks in unresectable locally advanced or metastatic HR-known/HER2-negative, PIK3CA/ PTEN-altered MpBC patients (Cohort B).

Upon meeting all selection criteria, 28 patients will be enrolled as follows:

- Cohort A: A run-in phase for safety and tolerability of MEN1611 in combination with eribulin will be conducted in this patient population (N=3). A Steering Committee decision/agreement is needed, after reviewing all toxicities, to expand this cohort with 11 additional patients (up to N=14).

Cohort B will be run only if positive finding in Cohort A, defined as ≥ 6 patients (42.9%) with achieved clinical benefit (CB) among 14 first recruited patients.

- Cohort B: Simon's two-stage minimax design. Stage I (N=7) will be initiated with MEN1611 monotherapy. This cohort will be stopped for futility if no responders (no complete response \[CR\] or partial response \[PR\]) are observed after 2 cycles among the first 7 patients included. Otherwise, Cohort B will be expanded with 7 additional patients for Stage II (up to N=14).

Recruitment & Eligibility

Status: Ongoing, recruiting

Sex: Not specified

Target Recruitment: 28

Inclusion Criteria

PRE-SCREENING PHASE: Patient must be able to sign written pre-screening informed consent form prior to any molecular determination during the pre-screening phase.

PRE-SCREENING PHASE: No prior treatment with a PI3K/AKT/mTOR inhibitors, nor with eribulin.

PRE-SCREENING PHASE: Patient must consent to give a tumor sample or/and a blood sample for testing of the prior mentioned alterations (or if needed and deemed safe by the investigator, able to provide a fresh tumor sample).

SCREENING PHASE: For women of childbearing potential: agreement to remain abstinent (must refrain from heterosexual intercourse) or use highly effective contraceptive methods, or two effective contraceptive methods, as defined in the CSP, during the treatment period and for at least 7 months after the last dose of Study treatment, whichever is longer. Women of childbearing potential must have a negative serum pregnancy test within 7 days before Study treatment initiation and must agree to refrain from donating eggs during the entire Study treatment period and for 3 months after the last administration of the Study drug.

PRE-SCREENING PHASE: Unknown PIK3CA mutational and PTEN loss status.

SCREENING PHASE: Patient must be able to sign written main informed consent form (ICF) prior to participation in any Study-related activities.

SCREENING PHASE: Adequate hematologic and organ function within 14 days before the first Study treatment on Day 1 of Cycle 1, defined by the following: a. Hematological (without platelet, red blood cell transfusion, and/or granulocyte colony-stimulating factor support within 7 days before first Study treatment dose): White blood cell (WBC) count > 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100.0 x109/L, and hemoglobin ≥ 9.0 g/dL (≥ 5.6 mmol/L). b. Hepatic: Serum albumin ≥ 3 g/dL; total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (≤ 3 x ULN in the case of Gilbert’s disease); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN (in the case of liver metastases ≤ 5 × ULN); alkaline phosphatase (ALP) ≤ 2 × ULN (≤ 5 × ULN in the case of liver and/or bone metastases). Note: If total bilirubin is increased, assessment of direct bilirubin levels is recommended. c. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min based on Cockcroft−Gault glomerular filtration rate estimation. d. Urinalysis: including dipstick (specific gravity, pH, glucose, protein, ketones, and blood) and microscopic examination (sediment, RBCs, WBCs, casts, crystals, epithelial cells, and bacteria).

SCREENING PHASE: Being male subjects, surgically sterile or having agreed with true abstinence (must refrain from heterosexual intercourse), or whose female partners are willing to agree with true abstinence or use barrier contraceptive measures mentioned above during the entire Study treatment period and for 7 months after the last administration of the Study drug. Males must agree to refrain from donating sperm during the entire Study treatment period and for 3 months after the last administration of the Study drug

SCREENING PHASE: Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1 which the Investigator believes is stable at the time of screening.

SCREENING PHASE: Patient must be accessible for treatment and follow-up.

SCREENING PHASE: Measurable, or non-measurable but evaluable, disease as defined by the local site Investigator as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria. Note: Patients with bone lesions as the only sites of metastatic disease are eligible.

SCREENING PHASE: Patient has a PIK3CA mutation confirmed by MEDSIR's designated central lab, determined in the pre-screening phase or patient has a pathology report confirming PIK3CA mutant status by a certified laboratory (using validated PIK3CA mutation assay) either from tissue or blood And/or Patient has evidence of PTEN loss by immunohistochemistry (IHC) confirmed by MEDSIR’s designated central lab in the pre-screening phase or patient has a pathology report confirming PTEN loss by a certified laboratory, preferably on the most recent available tumor sample. Note:. PI3KCA mutations should have been evaluated at least at hot spots, E542, E545 and H1047. PTEN staining should have been evaluated by assessing both intensity of staining and percentage of positive cells. Both nuclear and cytoplasmic staining should be evaluated. Staining of normal cells such as benign breast epithelium, stromal cells and/or endothelial cells should have been evaluated as an internal control. Any tumor nuclear or cytoplasmic staining showing similar intensity with internal control cells should have been considered positive staining (no PTEN loss). Complete lack of staining or faint staining (cytoplasmic or nuclear) in up to 50% of tumor cells should have been considered as PTEN loss. If there was no staining in internal control cells, the staining should have been considered inconclusive.

SCREENING PHASE: Life expectancy greater or equal to 12 weeks.

SCREENING PHASE: Unresectable locally advanced/metastatic MpBC documented by computed tomography (CT) scan or magnetic resonance imaging (MRI), that is not amenable to resection with curative intent.

SCREENING PHASE: Patients with clinically stable metastatic central nervous system (CNS) tumors are eligible if: a. Stereotactic radiotherapy ³ 7 days prior to initiation of study treatment. b. Whole-brain radiotherapy ³ 7 days prior to initiation of study treatment. c. Neurosurgical resection ³ 28 days prior to initiation of study treatment. d. Not receiving steroid therapy or anticonvulsant at Baseline

PRE-SCREENING PHASE: - Histologically confirmed metaplastic or non-metaplastic TNBC as per local assessment. or - Histologically confirmed HR-positive/HER2-negative metaplastic breast cancer

SCREENING PHASE: Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as determined by the US National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v.5.0). Note: Except for alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion

SCREENING PHASE: Available archival tumor sample (FFPE tissue) of the most recent biopsy/surgery since last progression. Note: Subjects for whom the most recent tumor biopsy since last progression could not be obtained (e.g., inaccessible tumor or subject safety concern) may submit archival pathological material from either metastatic or primary sites.

PRE-SCREENING PHASE: Being male or female aged ≥ 18 years

PRE-SCREENING PHASE: Known HR status according to the updated American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2020 guidelines and HER2-negative breast cancer (BC) as per ASCO/CAP 2018 criteria based on local testing on the most recently analyzed biopsy.

PRE-SCREENING PHASE: Prior treatment with at least one, but no more than four, prior lines of systemic therapy for advanced disease. Earlier adjuvant or neoadjuvant therapy for more limited disease will be considered as one of the required prior regimens if the development of unresectable locally advanced metastatic disease occurred within a 6-month period after completion of chemotherapy.

Exclusion Criteria

Current participation in another therapeutic clinical trial.

Uncontrolled diabetes mellitus (glycated haemoglobin [HbA1c] >7%) and/or fasting plasma glucose (FPG) >120 mg/dL or 6.7 mmol/L. Note: Patients who have DM adequately managed regardless FPG or HbA1c may be consider eligible as per the Medical Monitor assessment and criteria.

Known concurrent severe and/or uncontrolled concomitant medical conditions (i.e. influenza or any other active infections) that could cause unacceptable safety risks or compromise compliance with the protocol.

Known active or uncontrolled pulmonary dysfunction.

Current known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody [HBsAg] test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA

Known hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances.

Patient with serious and/or unstable pre-existing psychiatric or neurologic illness or other conditions that could interfere with subject safety.

History of significant gastrointestinal disease, including but not limited to abdominal fistula, gastrointestinal perforation or other malabsorption syndromes that would impact on drug absorption. Grade ≥2 diarrhea should resolve at least 7 days prior to the start of any Study treatment.

Subject receiving chronic treatment with steroids, as immunosuppressant, or another immunosuppressive agent.

Subject receiving treatment with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A as well as moderate or strong inducers of CYP1A2 within 2 weeks of the first administration of MEN1611.

Breastfeeding or pregnancy as determined by a serum pregnancy test (β-HCG) at screening, prior to the administration of MEN1611 either in monotherapy or in combination with eribulin. Since β-HCG over expression can be also elevated in some tumor types, a positive result should be confirmed with a validated alternative test (e.g., ultrasound).

Extra-cranial radiotherapy or limited-field palliative radiotherapy within 7 days prior to Study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade ≤ 1 and/or from whom ≥ 25% of the bone marrow has been previously irradiated.

Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 21 days of start of Study drug, or patients who have not recovered from the side effects of any major surgery.

Patient with a concurrent malignancy or malignancy within 5 years of Study enrollment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma, or stage I uterine cancer. Note: For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required.

Treatment with approved chemotherapy/immunotherapy/ targeted agents within 21 days prior to initiation of Study, or treatment with an investigational cancer therapy for 21 days or 5 half-lives (whichever is longer) prior to initiation of any Study treatment.

Patient with cerebrovascular accident or transient ischemic attack within 6 months prior to the start of any Study treatment.

Congenital long QT syndrome or screening QT interval corrected using Fridericia's formula (QTcF) > 480 milliseconds.

Patient with an active cardiac disease or a history of cardiac dysfunction or conduction abnormalities including any of the following: - Unstable angina pectoris or documented myocardial infarction within 6 months prior to Study entry. - Symptomatic pericarditis. - Documented congestive heart failure (New York Heart Association functional classification III- IV). - Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO). - Ventricular arrhythmias except for benign premature ventricular contractions. - Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication. - Conduction abnormality requiring a pacemaker. - Other cardiac arrhythmia not controlled with medication.

Patient with uncontrolled hypertension.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
CBR, defined as the percentage of patients who experience a complete response (CR), partial response (PR) or stable disease (SD) for at least 12 weeks after the start of treatment (MEN1611 in combination with eribulin), as determined locally by the Investigator per RECIST v1.1 criteria.		CBR, defined as the percentage of patients who experience a complete response (CR), partial response (PR) or stable disease (SD) for at least 12 weeks after the start of treatment (MEN1611 in combination with eribulin), as determined locally by the Investigator per RECIST v1.1 criteria.

Secondary Outcome Measures

Name	Time	Method
SECONDARY ENDPOINT: To assess the efficacy of MEN1611 in combination with eribulin as determined locally by the investigator as per RECIST v1.1 criteria by:		SECONDARY ENDPOINT: To assess the efficacy of MEN1611 in combination with eribulin as determined locally by the investigator as per RECIST v1.1 criteria by:
ORR defined as the proportion of patients with confirmed CR or PR.		ORR defined as the proportion of patients with confirmed CR or PR.
TTR defined as the time from the start of treatment to the first objective tumor response (tumor shrinkage of ≥ 30%).		TTR defined as the time from the start of treatment to the first objective tumor response (tumor shrinkage of ≥ 30%).
DoR defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first.		DoR defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first.
PFS defined as the time from the first dose of Study drugs until objective tumor progression or death, whichever occurs first.		PFS defined as the time from the first dose of Study drugs until objective tumor progression or death, whichever occurs first.
OS defined as the time from the first dose of Study drugs until death from any cause.		OS defined as the time from the first dose of Study drugs until death from any cause.
SECONDARY ENDPOINT: To evaluate the incidence of adverse events (AEs) as assessed by the investigator, with severity determined by NCI-CTCAE v.5.0 of MEN1611 in combination with eribulin.		SECONDARY ENDPOINT: To evaluate the incidence of adverse events (AEs) as assessed by the investigator, with severity determined by NCI-CTCAE v.5.0 of MEN1611 in combination with eribulin.

Trial Locations

Locations (13): Hospital Clinic De Barcelona
🇪🇸
Barcelona, Spain
Fundacion Instituto Valenciano De Oncologia
🇪🇸
Valencia, Spain
Hospital Universitario De Torrejon
🇪🇸
Torrejon De Ardoz, Spain
Complexo Hospitalario Universitario De Vigo
🇪🇸
Vigo, Spain
Hospital Clinico San Carlos
🇪🇸
Madrid, Spain
Hospital Universitari Vall D Hebron
🇪🇸
Barcelona, Spain
Hospital Universitario Virgen del Rocío
🇪🇸
Sevilla, Spain
Hospital Beata Maria Ana
🇪🇸
Madrid, Spain
Fundacion Onkologikoa Fundazioa
🇪🇸
Donostia, Spain
Institut Catala D'oncologia
🇪🇸
L'hospitalet De Llobregat, Spain
Scroll for more (3 remaining)
Hospital Clinic De Barcelona
🇪🇸Barcelona, Spain
Pablo Rene Rivera
Site contact
+34632924013
priverav@clinic.cat